---
title: "Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293923267.md"
description: "The company has announced its intention to file an Investigational New Drug (IND) application in the fourth quarter of 2026 and commence a Phase 1 study by the conclusion of the same year."
datetime: "2026-07-27T11:02:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293923267.md)
  - [en](https://longbridge.com/en/news/293923267.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293923267.md)
generator: "portal-rs"
---

# Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

The company has announced its intention to file an Investigational New Drug (IND) application in the fourth quarter of 2026 and commence a Phase 1 study by the conclusion of the same year.

### Related Stocks

- [NMRA.US](https://longbridge.com/en/quote/NMRA.US.md)

## Related News & Research

- [Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher](https://longbridge.com/en/news/297402586.md)
- [Neumora plans NMRA-215 clinical trial in 2026 after favorable toxicology results](https://longbridge.com/en/news/293920616.md)
- [Seven Elements appoints Florence Ng as independent non-executive director](https://longbridge.com/en/news/297639792.md)
- [CoinGecko: 2026 State of Crypto Security Report](https://longbridge.com/en/news/297471706.md)
- [CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference | CTSO Stock News](https://longbridge.com/en/news/298043682.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**